References
- McMahon BJ. The natural history of chronic hepatitis B virus infection. Semin Liver Dis. 2004;24(Suppl 1):17–21. PubMed | Google Scholar
- Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global
epidemiology of hepatitis B virus infection: new estimates
of age-specific HBs Ag seroprevalence and endemicity.
Vaccine. 2012;30(12):2212-19. Google
Scholar
- Mokdad AA, Lopez AD, Shahraz S, Lozano R, Mokdad AH, Stanaway J et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014;12:145. PubMed | Google Scholar
- Schweitzer A et al. Estimations of worldwide prevalence
of chronic hepatitis B virus infection: A systematic
review of data published between 1965 and 2013. Lancet.
2015;386(10003):1546-1555. Google
Scholar
- Sombié R, Bougouma A, Diallo O, Bonkoungou G, Cissé R
et al. Hépatite B chronique: aspects épidémiologique, diagnostique, thérapeutique
et évolutif au centre hospitalier universitaire Yalgado Ouédraogo de
Ouagadougou. J Afr Hépatol Gastroentérol. 2010; 4:3-10. Google
Scholar
- Causse X, Potier P, Labarrière D, Si-Ahmed SN. Le
porteur inactif du VHB existe-t-il? Hépato Gastro. 2016;23:739-744.
- Kissi Anzouan-Kacou YH, Doffou AS, Diallo D, Bangoura DA, Adéhouni Y, Kouamé HD et al. Treatment of Chronic Hepatitis B with Tenofovir Disoproxil Fumarate in Ivory Coast. Open Journal of Gastroenterology. 2016;6:39-45. Google Scholar
- Chen CJ, Yang HI, Su J et al. Risk of hepatocellular
carcinoma across a biological gradient of serum hepatitis
B virus DNA level. JAMA. 2006;295:65-73. Google
Scholar
- European Association for the Study of the Liver.
EASL Clinical Practice Guidelines: management of chronic
hepatitis B virus infection. J Hepatol. 2012;57:167-185. Google
Scholar
- Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013;381:468-475. PubMed | Google Scholar